Objective
Psoriasis is the most prevalent autoimmune disease, affecting approximately 125 million people worldwide. In Ireland alone it costs the health care system approximately 30 million euro yearly. Psoriasis is characterised by inflamed scaly red psoriatic plaques on the epidermis of sufferers and 20% of patients develop severe psoriasis, which is associated with an increased risk of cardiovascular disease and metabolic syndrome. Psoriasis can also be detrimental to a patient's psychological well-being. As there is no cure a psoriasis patient has a life-long struggle with managing the disease.
Anti-Interleukin-17 (IL-17) biologics that target IL-17A and IL-17 receptor A have proved successful in clinical trials in treating psoriasis, however, how IL-17 cytokines mediate the inflammatory effects in psoriasis pathogenesis remains incompletely understood. These biologic therapies, though highly efficacious, will remain unavailable to the majority of psoriasis patients due to their expense. New research findings suggest that there are more suitable therapeutic targets amongst the IL-17 cytokine and receptor families, which may not be as critical to the host’s response to infection, emphasising a need for new therapeutic strategies.
We propose to characterise the physiological role of IL-17 receptor D in psoriasis pathogenesis and present preliminary data to suggest that this role is protective. We also propose, with supporting data, that IL-17C may contribute to psoriasis pathogenesis by activating the IL-1 inflammasome and IL-17RD may regulate this. We propose to use a psoriasiform disease model in Il-17rd-deficient mice to characterise its function and samples from psoriasis patients to isolate primary keratinocytes to dissect IL-17C signalling pathways.
Determining the roles of IL-17C and IL-17RD will aid in finally treating psoriasis effectively and would also aid in comprehending the role of dysregulated IL-17 signalling in other chronic inflammatory diseases.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences inflammatory diseases
- medical and health sciences basic medicine immunology autoimmune diseases
- medical and health sciences clinical medicine cardiology cardiovascular diseases
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2013-IEF
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
8006 ZURICH
Switzerland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.